Logo

Novartis Receives EU Approval for Gene Therapy Luxturna (voretigene neparvovec) in Patients with Rare Inherited Retinal Disease

Share this

Novartis Receives EU Approval for Gene Therapy Luxturna (voretigene neparvovec) in Patients with Rare Inherited Retinal Disease

Shots:
  • The approval is based on P-III trial- involving assesment of Luxturna vs control group patients- with inherited retinal disease (caused due to mutation in both copies of the RPE65 gene and sufficient viable retinal cells)
  • Results: Vision improvement recorded @ 30 days following treatment- @1yr. MLMT (multi-luminance mobility test) (1.6); 65% patients successfully navigate the MLMT at the lowest light level of 1 lux
  • Luxturna is gene therapy to restore vision is designed to provide a working copy of the RPE65 gene to act in place of the mutated RPE65 gene and currently marketed by Spark Therapeutics in the US
/ article | Ref: Novartis | Image: Pharmaceutical Technology

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions